These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

332 related items for PubMed ID: 12968412

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Palmar-plantar erythrodysesthesia (PPE): a literature review with commentary on experience in a cancer centre.
    Webster-Gandy JD, How C, Harrold K.
    Eur J Oncol Nurs; 2007 Jul; 11(3):238-46. PubMed ID: 17350337
    [Abstract] [Full Text] [Related]

  • 3. Penile involvement with hand-foot syndrome.
    Sorscher SM.
    Am J Clin Dermatol; 2004 Jul; 5(3):209-10. PubMed ID: 15186201
    [Abstract] [Full Text] [Related]

  • 4. Increased mast cell density in capecitabine-induced hand-foot syndrome: a new pathologic finding.
    Latif S, Fraga G, Gadzia J.
    J Drugs Dermatol; 2010 Mar; 9(3):268-70. PubMed ID: 20232590
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Randomized trial of two different doses of pyridoxine in the prevention of capecitabine-associated palmar-plantar erythrodysesthesia.
    Chalermchai T, Tantiphlachiva K, Suwanrusme H, Voravud N, Sriuranpong V.
    Asia Pac J Clin Oncol; 2010 Sep; 6(3):155-60. PubMed ID: 20887495
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Predisposing risk factors for palmar-plantar erythrodysesthesia when using liposomal doxorubicin to treat recurrent ovarian cancer.
    Tanyi JL, Smith JA, Ramos L, Parker CL, Munsell MF, Wolf JK.
    Gynecol Oncol; 2009 Aug; 114(2):219-24. PubMed ID: 19446868
    [Abstract] [Full Text] [Related]

  • 12. Elevated body mass index does not increase the risk of palmar-plantar erythrodysesthesia in patients receiving pegylated liposomal doxorubicin.
    Gordinier ME, Dizon DS, Fleming EL, Weitzen S, Schwartz J, Parker LP, Granai CO.
    Gynecol Oncol; 2006 Oct; 103(1):72-4. PubMed ID: 16494932
    [Abstract] [Full Text] [Related]

  • 13. Palmar-plantar erythrodysesthesia due to docetaxel-capecitabine therapy is treated with vitamin E without dose reduction.
    Kara IO, Sahin B, Erkisi M.
    Breast; 2006 Jun; 15(3):414-24. PubMed ID: 16188440
    [Abstract] [Full Text] [Related]

  • 14. Hand-foot syndrome (hand-foot skin reaction, palmar-plantar erythrodysesthesia): focus on sorafenib and sunitinib.
    Lipworth AD, Robert C, Zhu AX.
    Oncology; 2009 Jun; 77(5):257-71. PubMed ID: 19923864
    [Abstract] [Full Text] [Related]

  • 15. [Blisters unlike others].
    Gugerli O, Leupin N.
    Rev Med Suisse; 2006 Apr 19; 2(62):1076-7. PubMed ID: 16711153
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Hand-foot syndrome associated with short infusions of combination chemotherapy with gemcitabine and vinorelbine.
    Laack E, Mende T, Knuffmann C, Hossfeld DK.
    Ann Oncol; 2001 Dec 19; 12(12):1761-3. PubMed ID: 11843256
    [Abstract] [Full Text] [Related]

  • 19. [A case of severe hand-foot syndrome caused by capecitabine].
    Shimomatsuya T, Mitsudou Y, Nakamura T, Yonezawa K, Shiraishi S, Fujino M, Maruhashi K.
    Gan To Kagaku Ryoho; 2007 Jul 19; 34(7):1139-41. PubMed ID: 17637558
    [Abstract] [Full Text] [Related]

  • 20. Chemotherapy-induced palmer planter erythrodysesthesia.
    Bhasin S, Sunita, Gupta DK, Kataria SP, Saluja S, Sharma M.
    J Assoc Physicians India; 2005 Feb 19; 53():155-6. PubMed ID: 15847041
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.